EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Durable Response to Durvalumab in Occult Small‐Cell Lung Cancer With Immune Checkpoint Inhibitor–Related Inflammatory Arthritis With Polymyalgia Rheumatica–Like Features

Akihito Fujimi, Naofumi Yamauchi, Ken Sato, Yasuhiro Nagamachi, Takuji Nishisato, Kohichi Takada iD

Geriatrics & Gerontology International · 2026

DOI: 10.1111/ggi.70678 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Geriatrics & Gerontology International, 2026. Verfasst von Akihito Fujimi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Sapporo Kiyota Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Agents, Immunological, Arthritis, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report a case of occult small-cell lung cancer with durable disease control during durvalumab therapy for 51 months. The patient developed immune checkpoint inhibitor-related inflammatory arthritis with polymyalgia rheumatica-like features, highlighting diagnostic challenges and the importance of functional independence in older adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalArthritisImmune Checkpoint InhibitorsLung NeoplasmsPolymyalgia RheumaticaSmall Cell Lung CarcinomaAgedHumansMale

Substanzen

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicaldurvalumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, Sapporo Kiyota Hospital, Sapporo, Japan.
  • Department of Rheumatology, Sapporo Kiyota Hospital, Sapporo, Japan.
  • Department of Internal Medicine, Sapporo Kiyota Hospital, Sapporo, Japan.
  • Department of Medical Oncology, Sapporo Medical University, Sapporo, Japan.

ORCID-Profile: Kohichi Takada

Zitieren

APA

Fujimi, A., Yamauchi, N., Sato, K., Nagamachi, Y., Nishisato, T., & Takada, K. (2026). Durable Response to Durvalumab in Occult Small‐Cell Lung Cancer With Immune Checkpoint Inhibitor–Related Inflammatory Arthritis With Polymyalgia Rheumatica–Like Features. Geriatrics & Gerontology International. https://doi.org/10.1111/ggi.70678

Vancouver

Fujimi A, Yamauchi N, Sato K, Nagamachi Y, Nishisato T, Takada K. Durable Response to Durvalumab in Occult Small‐Cell Lung Cancer With Immune Checkpoint Inhibitor–Related Inflammatory Arthritis With Polymyalgia Rheumatica–Like Features. Geriatrics & Gerontology International. 2026. doi:10.1111/ggi.70678

BibTeX
@article{Fujimi2026,
  author = {Fujimi, Akihito and Yamauchi, Naofumi and Sato, Ken and Nagamachi, Yasuhiro and Nishisato, Takuji and Takada, Kohichi},
  title = {Durable Response to Durvalumab in Occult Small‐Cell Lung Cancer With Immune Checkpoint Inhibitor–Related Inflammatory Arthritis With Polymyalgia Rheumatica–Like Features},
  journal = {Geriatrics & Gerontology International},
  year = {2026},
  doi = {10.1111/ggi.70678}
}
Kostenlos starten →